Yorktown Management & Research Company’s Enanta Pharmaceuticals ENTA Stock Holding History

Yorktown Management & Research Company’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,400	Closed	-$778K	–	236
2021 Q4	$778K	Hold	10,400	–	–	0.53%	42
2021 Q3	$591K	Hold	10,400	–	–	0.44%	67
2021 Q2	$458K	Buy	10,400 +5,900	+131%	+$289K	0.36%	122
2021 Q1	$222K	Buy	+4,500	New	+$224K	0.18%	226
2020 Q4	–	Sell	-4,500	Closed	-$206K	–	231
2020 Q3	$206K	Hold	4,500	–	–	0.19%	235
2020 Q2	$226K	Hold	4,500	–	–	0.2%	247
2020 Q1	$231K	Buy	+4,500	New	+$240K	0.23%	186
2019 Q3	–	Sell	-6,034	Closed	-$509K	–	311
2019 Q2	$509K	Hold	6,034	–	–	0.19%	142
2019 Q1	$576K	Hold	6,034	–	–	0.19%	139
2018 Q4	$427K	Buy	6,034 +358	+6%	+$27.4K	0.14%	163
2018 Q3	$485K	Buy	5,676 +479	+9%	+$48K	0.14%	165
2018 Q2	$602K	Buy	+5,197	New	+$519K	0.17%	137

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Yorktown Management & Research Company's ENTA Position: Q1 2022 in Review

Yorktown Management & Research Company sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 10,400 shares — an estimated $778K sold.

Yorktown Management & Research Company first reported a position in ENTA in Q2 2018 and held it in 12 quarters. The position peaked at $778K in Q4 2021. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

Yorktown Management & Research Company reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Yorktown Management & Research Company sold 10,400 Enanta Pharmaceuticals shares in Q1 2022, an estimated $778K.
Yorktown Management & Research Company first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 12 quarters.
Yorktown Management & Research Company's Enanta Pharmaceuticals position peaked at $778K in Q4 2021.
169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on Yorktown Management & Research Company's 13F filing for Q1 2022, filed 29 Apr 2022.